Evidence map›Paper›PMID 34776944›Full record

ReviewFrontiers in pharmacology2021

Risk of Malignancy and Tuberculosis of Biological and Targeted Drug in Patients With Spondyloarthritis: Systematic Review and Meta-analysis of Randomized Controlled Trials.

Siliang Man, Lidong Hu, Xiaojian Ji, Yiwen Wang, Yingpei Ma, Lei Wang, Jian Zhu, Feng Huang

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Siliang ManDepartment of Rheumatology, Beijing Jishuitan Hospital, Beijing, China.
Lidong HuSchool of Medicine, Xiamen University, Xiamen, China.
Xiaojian JiDepartment of Rheumatology and Immunology, the First Medical Centre, Chinese PLA General Hospital, Beijing, China.
Yiwen WangDepartment of Rheumatology and Immunology, the First Medical Centre, Chinese PLA General Hospital, Beijing, China.
Yingpei MaDepartment of Rheumatology and Immunology, the First Medical Centre, Chinese PLA General Hospital, Beijing, China.
Lei WangDepartment of Rheumatology and Immunology, the First Medical Centre, Chinese PLA General Hospital, Beijing, China.
Jian ZhuDepartment of Rheumatology and Immunology, the First Medical Centre, Chinese PLA General Hospital, Beijing, China.
Feng HuangDepartment of Rheumatology and Immunology, the First Medical Centre, Chinese PLA General Hospital, Beijing, China.
Chinese PLA General Hospital · CNPeking University · CNXiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biologic therapymalignancyspondyloarthritissystematic review and meta-analysistuberculosis

Identifiers

PMID34776944
PMCPMC8585981
OpenAlexW3209223984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.